Source comparison
Research Applications: Tissue-Specific vs Systemic Outcomes
Follistatin-344 research concentrates on conditions where myostatin overexpression or muscle wasting is the primary pathology. Studies published in the Journal of Cachexia, Sarcopenia and Muscle have investigated follistatin gene therapy for Duchenne muscular
This comparison does not assign a generated winner or score.
- Follistatin-344 research concentrates on conditions where myostatin overexpression or muscle wasting is the primary pathology. Studies published in the Journal of Cachexia, Sarcopenia and Muscle have investigated follistatin gene therapy for Duchenne muscular dystrophy, where myostatin inhibition partially compensated for dystrophin deficiency. Other research examines follistatin's role in reducing hepatic and cardiac fibrosis. Activin A, another follistatin ligand, promotes fibroblast activation, so sequestering it with follistatin reduces extracellular matrix deposition. A 2021 animal trial found that follistatin administration reduced liver fibrosis scores by 40% in a NASH model over 16 weeks.
- Sermorelin research focuses on growth hormone deficiency states, metabolic syndrome, sleep disturbances, and body composition changes associated with aging. Because Sermorelin stimulates endogenous GH rather than providing exogenous hormone, it preserves feedback regulation. Unlike synthetic GH, which can suppress endogenous production. Clinical research has used Sermorelin to study improvements in lean body mass (mean increase 1.8kg over 6 months), visceral fat reduction (12–15% decrease), and REM sleep duration (increased by 18 minutes per night). The peptide has also been investigated as a diagnostic tool. Impaired GH response to Sermorelin indicates pituitary hypofunction rather than hypothalamic pathology.
- The research overlap is minimal: follistatin addresses localized tissue remodeling and muscle mass regulation independent of growth hormone; Sermorelin modulates systemic metabolic and anabolic processes downstream of GH-IGF-1 signaling. Investigators examining muscle hypertrophy mechanisms at the molecular level use follistatin; those studying whole-body metabolic effects or hormonal restoration use Sermorelin. Real Peptides clients running comparative studies often use both peptides in separate experimental arms to differentiate myostatin-dependent vs GH-dependent outcomes.